State of New Jersey Common Pension Fund D Has $3.26 Million Position in Moderna, Inc. $MRNA

Key Points

• The State of New Jersey Common Pension Fund D has decreased its stake in Moderna, Inc. by 7.6%, owning 114,822 shares after selling 9,409 shares, valued at approximately $3.25 million.
• Institutional investors hold a majority of Moderna's stock, with 75.33% ownership, including significant increases from firms like Deutsche Bank AG and Wealthfront Advisers LLC.
• Recent analyst ratings indicate a consensus rating of "Hold" with a target price averaging $43.59, amidst a reported earnings loss and decreasing revenues year-over-year.

State of New Jersey Common Pension Fund D trimmed its holdings in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 7.6% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 114,822 shares of the company's stock after selling 9,409 shares during the quarter. State of New Jersey Common Pension Fund D's holdings in Moderna were worth $3,255,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of MRNA. S Bank Fund Management Ltd bought a new stake in shares of Moderna in the first quarter valued at approximately $25,000. Costello Asset Management INC bought a new stake in shares of Moderna in the first quarter valued at approximately $30,000. Sentry Investment Management LLC bought a new stake in shares of Moderna in the first quarter valued at approximately $31,000. Deseret Mutual Benefit Administrators boosted its position in shares of Moderna by 53.3% in the first quarter. Deseret Mutual Benefit Administrators now owns 1,128 shares of the company's stock valued at $32,000 after acquiring an additional 392 shares during the period. Finally, Itau Unibanco Holding S.A. boosted its position in shares of Moderna by 51.2% in the fourth quarter. Itau Unibanco Holding S.A. now owns 1,013 shares of the company's stock valued at $42,000 after acquiring an additional 343 shares during the period. 75.33% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research firms have recently weighed in on MRNA. Bank of America reduced their price objective on Moderna from $26.00 to $25.00 and set an "underperform" rating for the company in a research report on Tuesday, July 22nd. Evercore ISI set a $32.00 target price on Moderna in a research note on Friday, August 1st. UBS Group cut their target price on Moderna from $78.00 to $70.00 and set a "buy" rating for the company in a research note on Friday, May 2nd. Barclays cut their target price on Moderna from $40.00 to $31.00 and set an "equal weight" rating for the company in a research note on Monday, August 4th. Finally, Leerink Partners cut their target price on Moderna from $18.00 to $15.00 and set an "underperform" rating for the company in a research note on Friday. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, sixteen have assigned a Hold rating and four have given a Sell rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and an average price target of $42.88.

Moderna Stock Up 3.4%

NASDAQ:MRNA traded up $0.90 during trading hours on Friday, reaching $27.12. The company had a trading volume of 9,158,832 shares, compared to its average volume of 8,197,467. The stock has a 50-day moving average of $29.18 and a two-hundred day moving average of $29.08. Moderna, Inc. has a one year low of $23.15 and a one year high of $84.28. The firm has a market capitalization of $10.55 billion, a PE ratio of -3.60 and a beta of 1.83.

Moderna (NASDAQ:MRNA - Get Free Report) last announced its quarterly earnings results on Friday, August 1st. The company reported ($2.13) earnings per share for the quarter, beating analysts' consensus estimates of ($2.99) by $0.86. Moderna had a negative return on equity of 25.96% and a negative net margin of 94.31%.The firm had revenue of $142.00 million for the quarter, compared to analysts' expectations of $116.26 million. During the same period in the prior year, the business posted ($3.33) earnings per share. The business's revenue was down 41.1% compared to the same quarter last year. Moderna has set its FY 2025 guidance at EPS. As a group, sell-side analysts expect that Moderna, Inc. will post -9.61 earnings per share for the current year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.